Increased Expression of Glucocorticoid Receptorβ Messenger RNA in Patients with Ankylosing Spondylitis

Chang-Keun Lee, M.D., Eun Young Lee, M.D., You-Sook Cho, M.D., Keun Ae Moon2, Bin Yoo, M.D. and Hee-Bom Moon, M.D.

Division of Allergy and Rheumatology, Department of Internal Medicine, Asan Institute for Life Science2, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Background : Glucocorticoids have been known to be less effective for treating ankylosing spondylitis (AS) patients than for treating rheumatoid arthritis (RA) patients. To elucidate the mechanisms underlying this phenomenon, we evaluated whether the glucocorticoid receptor (GR)β expression of the peripheral blood mononuclear cells (PBMCs) in patients with AS is increased compared with patients with RA.

Methods : PBMCs were isolated from the subjects of 3 study groups: the healthy controls (n=25), the RA patients (n=25), and the AS patients (n=25). All the subjects had never taken corticosteroids and the patients with RA or AS were newly diagnosed. The expression of GRβ messenger RNA (mRNA) was determined by reverse transcription of the total RNA, and this was followed by semi-quantitative polymerase chain reaction analysis (RT-PCR).

Results : The level of GRα mRNA expression was not different among three groups. GRβ mRNA expression of the AS patients (2.02 [range: 0.99-7.21], median [25th-75th percentiles]) was enhanced compared with that of the controls (0.78 [range: 0.43-1.62]) and the RA patients (0.98 [range: 0.79-1.18]). The level of GRβ mRNA expression was not related to the inflammatory markers or the disease activity score 28 for the RA patients, and it was not related to the Bath ankylosing spondylitis disease activity index for the AS patients.

Conclusion : The expression of GRβ mRNA, which is a dominant negative regulator for the glucocorticoid response, was increased in AS patients. The results suggest that the increased expression of GRβ mRNA may be related to the ineffectiveness of glucocorticoids for the treatment of AS.

Key Words : Ankylosing Spondylitis, Glucocorticoid Receptor, Rheumatoid Arthritis

INTRODUCTION

Glucocorticoids were used therapeutically for the first time to treat a 28-year-old woman with crippling rheumatoid arthritis (RA)1), and the result was dramatic. Since then, glucocorticoids have earned a reputation as being the only drug that can reliably, effectively and rapidly suppresses the symptoms and signs of synovitis in RA. The evidence that glucocorticoids are effective, in the short term, on selected measures of disease activity has been reviewed in a recent meta-analysis2). However, to date, no studies have been performed to evaluate the effectiveness of continuous oral glucocorticoid treatment for ankylosing spondylitis (AS). According to the clinical experience, oral glucocorticoid treatment is clearly less effective for AS than for RA. The glucocorticoid receptor (GR) is essential for the action of glucocorticoid on various effector cells. The existence of two highly homologous glucocorticoid receptor isoforms, namely GRα and GRβ, which differ only at their C-termini,
was predicted by sequencing the human GR cDNA and the gene. Both GRα and GRβ are products of alternative splicing of the primary transcript of GR messenger RNA (mRNA). GR α is a ligand-activated transcription factor that modulates the expression of glucocorticoid-responsive genes by binding to specific glucocorticoid response elements (GREs), whereas GR β does not bind glucocorticoids and it is transcriptionally inactive. It has been suggested that GRβ may be an endogenous inhibitor of glucocorticoid action and it may be an important dominant negative regulator for determining glucocorticoid sensitivity in the target tissues. The increased expression of GRβ was recently reported in patients with glucocorticoid-insensitive asthma and ulcerative colitis. To test the possibility that the ineffectiveness of oral glucocorticoid for the treatment of AS may be associated with a higher expression of GRβ, we compared the expression of GRβ in newly diagnosed RA and AS patients.

**MATERIALS AND METHODS**

**Patients and clinical data**

Twenty five RA patients and 25 AS patients were recruited from the outpatient clinic of Asan Medical Center in Korea from January 2001 to November 2001. The diagnosis of AS was made when the patients met the modified New York criteria. A diagnosis of RA was made when the patients fulfilled the American Rheumatism Association 1987 revised criteria for the classification of RA. Twenty five healthy volunteers were recruited as controls. The patients with AS or RA were newly diagnosed and they had never taken glucocorticoids. Informed consents were obtained from all the patients and controls. Heparinized blood (30 mL) was donated by the patients with AS or RA, and the healthy controls. Peripheral blood mononuclear cells (PBMCs) were isolated from these blood samples by the Ficoll-paque density gradient method (Amersham Pharmacia Biotech, Uppsala, Sweden).

The demographic data of the patients were recorded. The acute phase reactants, the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), were measured. The ESR was calculated by the Westergren method (normal 0–9 mm/hr) and the CRP was measured qualitatively by immunonephelometry (N Latex CRP mono, Behring Diagnostics, San Jose, CA, USA) (normal CPR level: 0–0.6 mg/dL). In the current study, the disease activity of AS is reported in the form of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). The disease activity of RA is reported in the form of 28 Disease Activity Score (DAS28), which is a validated composite index measuring the swollen joint count (28 joints), the tender joint count (28 joints), the ESR and the patient’s overall assessment of well-being.

**Detection of GR and GR mRNA**

The expression of GRα and GRβ mRNA was determined by reverse transcription of the total RNA followed by polymerase chain reaction analysis (RT-PCR). The RNA was extracted by using an RNA Isolation Kit (Promega, Madison, WI, USA). The cDNAs were synthesized by extension of the oligo(dT) primers (Promega) with using mouse mammary leukemia virus (MMLV) reverse transcriptase (Promega). PCR of the cDNAs was performed with the common upstream primer (5′-CCTAAGGAC GTCTGAAGAGC-3′, corresponding to nucleotides 2158–2178 of the GRα and GRβ cDNA) and the specific downstream primers (GRα: 5′-GCCAAGTCTTGGCCCTCTAT-3′, complementary to nucleotides 2616–2635 of GRα cDNA; and GRβ: 5′-CCACGTATC CTAAAGGGCAC-3′, complementary to nucleotides 2503–2523 of GRβ cDNA). The transcript of human glucose-3-phosphate dehydrogenase (GPDH) was amplified from the same cDNA samples to serve as a control for sample loading and integrity. The PCR of GPDH was performed with a sense primer (5′-ACCACAGTCCATGCCATCAC-3′) and an antisense primer (5′-TCCTCCACCTGTGTGCTGCA-3′). Each PCR procedure was carried out in a total volume of 50 μL containing 34.75 μL of distilled water, 5 μL of cDNA, 5 μL of 10 x PCR buffer (Promega) 1 μL of each primer, 0.25 μL of Taq DNA polymerase, 1 μL of dNTP and 3 μL of MgCl₂. After an initial denaturation period of 5 minutes at 95 °C, and then 36 cycles (for GRα and GPDH) or 46 cycles (for GRβ), consisting of incubations at 94 °C for 30 seconds, 60 °C for 30 seconds, and 72 °C for 1 minute, were carried out. After a final extension step for 10 minutes at 72 °C, the PCR products were separated by electrophoresis on a 1.0% agarose gel and then they were visualized by ethidium bromide staining. The intensity of the ethidium bromide fluorescence was measured densitometrically. The density of each PCR products was adjusted according to the density of GPDH.

**Statistics**

Statistical differences in the expressions of GRα and GRβ mRNA were tested for by the Kruskal–Wallis test and the Mann–Whitney test. The relationships between the expressions of GR and GR mRNA and the ESR, CRP, BASDAI, DAS28 and RF were analyzed by the Spearman correlation test. p values of <0.05 were considered as being statistically significant.

**RESULTS**

**Patients and clinical data**

The demographic, clinical and laboratory data are shown in
Table 1. Demographic, clinical and laboratory data

|                | Control (n=25) | RA (n=25) | AS (n=25) | p Value |
|----------------|---------------|-----------|-----------|---------|
| Age            | 27.8±2.8      | 46.2±13.8 | 30.8±8.7  | 0.01*   |
| Gender (M/F)   | 20/5          | 4/21      | 21/4      | 0.01*   |
| ESR (mm/hr)    | 52.6±30.6     | 44.6±36.2 | 2.27±3.2  | 0.43    |
| CRP (mg/dL)    | 2.9±4.1       | 3.7±2.1   |           | 0.56    |
| BASDAI         |               |           |           |         |
| DAS28          | 4.3±0.9       | 4.3±4     | 6.5±2.5   |         |
| Tender joint count |       | 3.9±2.9   | 6.8±2.2   |         |
| Swollen joint count |       |           |           |         |
| PGA (0–10 cm)  | 11.64 [7.87–16.49] | 17.74 [9.92–26.26] | 0.34 |
| VAS (0–10 cm)  | 0.78 [0.43–1.62] | 0.98 [0.79–1.18] | 2.02 [0.99–7.21] | 0.01* |
| GRα/GPDH /     | 0.08 [0.03–0.22] | 0.09 [0.05–0.14] | 0.15 [0.080.45] | 0.02- |
| GRβ/GPDH /     |               |           |           |         |

Values are means ± standard deviation. † is expressed as the median [25th–75th percentiles]. RA, rheumatoid arthritis; AS, ankylosing spondylitis; M, male; F, female; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAS28, Disease Activity Score 28; PGA, patient global assessment; VAS, visual analogue pain scale; GRα, glucocorticoid receptor alpha; GRβ, glucocorticoid receptor beta

RA, p<0.05 by ANOVA, †p<0.05 by chi-square test, *p<0.05 by Kruskal–Wallis test

Table 1. As expected, there were differences for age and gender between the RA and AS patients. The elevated values of the mean ESR and the mean CRP were observed in both the RA and AS patients. For those patients with RA, 22 patients (80%) were rheumatoid factor positive. The mean DAS 28 was 4.3±0.9 (mean±standard deviation), with a range of 2.3–6.9, which indicated the active stage of RA. In patients with AS, 25 patients (100%) were positive for human leukocyte antigens (HLA) B27. The mean BASDAI was 3.7±2.1, with a range of 1.3–9.8.

Expression of GRα and GRβ mRNA

As shown in Figure 1A, the RT–PCR product of GRα mRNA (477 base pairs [bp]) was detectable in all the samples we tested including the healthy controls and the patients with RA or AS. The level of expression of GRα mRNA, when normalized to GPDH, were not different among the three groups (control: 13.09 [range: 4.70–24.63] [median 25th–75th percentiles]), RA: 11.64 [range: 7.87–16.49], AS: 17.74 [range: 9.92–26.26], p=0.34) (Figure 2A). Among the 25 patients with AS, the RT–PCR product of GRβ mRNA (365 bp) was detected in 17 patients (68%). In contrast, GRβ mRNA was detected in only 5 of the 25 patients with RA (20%) and in only 9 of the 25 healthy controls (30%) (Figure 1B). The expression level of GRβ mRNA, when normalized to GPDH, was higher in patients with AS (2.02 [range: 0.99–7.21]) than that of the RA patients (0.98 [range: 0.79–1.18]) and the controls (0.78 [range: 0.43–1.62]) (p=0.01) (Figure 2B).

Relationship between the expression of GRα and GRβ mRNA and the clinical data

To assess what clinical factors are associated with the expression of GRα and GRβ mRNA, BASDAI, DAS28, ESR, CRP, RF, the tender joint count, the swollen joint count, the patients’ global assessment (PGA), and their visual analogue
Chang-Keun Lee, et al: Glucocorticoid receptorβ in ankylosing spondylitis

GRα mRNA expression

Figure 2. Densitometric analysis of GR mRNA expression normalized to GPDH. (A) The level of GRα mRNA expression was not different among three groups. (B) The expression of GRβ mRNA was higher for AS patients than that for the RA and control patients. Boxes represent the 25th to 75th percentile; vertical lines indicate the 5th and 95th percentile. Statistical difference is indicated as *p < 0.05 by Mann-Whitney test.

DISCUSSION

Glucocorticoids are used widely as treatment for the suppression of inflammation in chronic inflammatory diseases. However, some of the patients with autoimmune diseases who are treated with glucocorticoids often fail to respond to glucocorticoids. This is called immune system–specific glucocorticoid resistance and it appears to be the results of tissue–specific defects of the GR transduction system. This condition might be genetically/constitutionally determined. There might be several mechanisms responsible for this phenomenon, including changes in the intracellular hormone availability, the levels of cellular GRα and the hormone–binding affinity. Other mechanisms could involve phosphorylation, nuclear translocation, GRE binding and/or its interaction with other nuclear factors, as well as abnormally high levels of GRβ.

Based on clinical experience, glucocorticoid treatment is known to be less effective for AS than RA. Among the several mechanisms of glucocorticoid resistance, we investigated the levels of GRβ in the PBMCs from patients with RA or AS. In the present study, we demonstrated that GRβ mRNA expression was significantly increased in the PBMCs from patients with AS compared with that of the healthy controls and the patients with RA. The pathophysiological factors that induce the enhanced expression of GRβ mRNA in AS patients are not yet clear. It may be possible that systemic inflammation may cause the increase expression of GRβ mRNA in AS patients. However, we did not find any correlation between the inflammatory markers (ESR and CRP) and the expression level of GRβ mRNA in the AS patients. BASDAI also did not affect the level of expression of GRβ mRNA in the AS patients. For the patients with RA, the DAS 28, which included the swollen joint count, the tender joint count, ESR and the patients’ overall assessment of well-being, was not associated with the expression of GRβ mRNA. These results suggest that GRβ mRNA expression in the PBMCs is not induced by an inflammatory reaction for the patients with AS or RA.

A genetically determined imbalance of the glucocorticoid receptor isoforms was found in the cultured lymphocytes from a patient suffering from chronic leukemia and having congenital generalized glucocorticoid resistance. This patient presented with a greatly reduced GRα level and a normal GRβ level, and this resulted in a low GRα to GRβ ratio. However, there was no difference for the GRα mRNA expression among the three groups in our study. For the patients with AS, the decreased expression of GRα mRNA was not found compared to the patients with RA.

It is unclear if a low dose of glucocorticoid can induce GR expression. Korn et al have reported an unchanged splicing level of GRβ mRNA in bronchial epithelial cells after they were exposed to glucocorticoid reagents in vivo. To exclude the...
potential effect of glucocorticoids on the splicing of GRβ mRNA, we selected patients who have never taken glucocorticoid.

The various effects of glucocorticoid are mediated by specific intracellular glucocorticoid receptors. GRα and GRβ are products of alternative splicing in exon 9 of the gene encoding GR, and this gene is located on chromosome 5q. In contrast to GRα, GRβ does not bind glucocorticoids in vitro and it is transcriptionally inactive on a GRE-containing enhancer. The expression of GRβ mRNA has been demonstrated by RT–PCR for a variety of human tissues, but the level of GRβ mRNA was relatively low and it was considered to be 0.2~0.3% of the GRα mRNA. Bomberger et al. showed that the increased production of GRβ compared with GRα could disrupt the enhancing effects of GRα in COS-7 cells. Oakely et al. also demonstrated the GRβ dominant negative activity in HeLa-S3 cells that have endogenous GRα receptors, and this activity was also regulated in a GRE-mediated manner. The potential mechanisms responsible for this dominant negative effect exerted by GRβ have not yet been elucidated. The mechanism might involve competition between GRα and GRβ for GRE binding, formation of transcriptionally inactive or partially active GRα–GRβ, and/or competition for the stoichiometrically limited concentrations of the coactivators that are needed by GRα for full transcriptional activity.

On the contrary, Hecht et al. found no evidence for a specific dominant negative effect of GRβ on the trans-activation induced by GRα. Also, cotransfection of GRβ in primary human lymphocytes or Jurkat T lymphoma cells had no effect on trans-activation by the GRα isoforms, even when the GRβ protein was found at greater than five times the levels of GRα.

These discrepancies seem to be the results of using different vectors, the different cell/tissue specificities and the limitations of the cotransfection experiments. In contrast to the controversial nature of in vitro experiments at the cellular level of GRβ action, evidence is now accumulating that indicates the relationship between the GRβ expression and the glucocorticoid responsiveness of organs or individuals in vivo. Hamid et al. reported that the GRβ positive PBMCs or bronchoalveolar lavage cells are significantly increased in glucocorticoid-resistant patients with bronchial asthma. Honda et al. showed that the positive rate of GRβ mRNA detected by RT–PCR was higher for glucocorticoid resistant ulcerative colitis patients than for glucocorticoid sensitive patients. Our results also showed the relationship between glucocorticoid unresponsiveness and GRβ mRNA expression in AS patients. Further experiments regarding glucocorticoid binding affinity, the rate of GR nuclear translocation and its interaction with other nuclear factor are required to reveal the mechanisms that are responsible for the ineffectiveness of glucocorticoids in AS patients.

In summary, we found the increased expression of GRβ mRNA in AS patients compared with RA patients. These previously unreported results suggest the possibility that the increased expression of GRβ may be associated with the ineffectiveness of continuous oral glucocorticoid treatment for AS.

ACKNOWLEDGEMENT

This study was supported by a grant (grant number 2001-066) from the Asan Institute for Life Sciences, Seoul, Korea.

REFERENCES

1) Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc 24:181-197, 1949
2) Gotzsche PC, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:311-318, 1998
3) Hollenberg SM, Weinberger C, Ong ES, Carelli G, Oro A, Lebo R. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 159:1600-1604, 1999
4) Bomberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95:2435-2441, 1995
5) Bamberger CM, Shulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 17:245-261, 1996
6) Hamid QA, Wenzel SE, Hauk PJ, Tiscopoulou A, Wallaert B, Lafitte JJ, Chrousos GP, Szelifer SJ, Leung DY. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 159:1600-1604, 1999
7) Honda M, Oni F, Ayabe T, Imai S, Ashida T, Obara T, Kohgo Y. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 118:859-866, 2000
8) van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361-368, 1984
9) Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinsals RS, Schaller JG, Sharp JT, Wider RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988
10) Garrett S, Jenkinson T, Kennedy LG, Whitehall H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis. J Rheumatol 21:2286-2291, 1994
11) Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include
twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48, 1995

12) Barnes PJ, Adcock IM. Steroid resistance in asthma. QJM 88:455–468, 1995

13) Szefler SJ, Leung DY. Glucocorticoid resistant asthma: pathogenesis and clinical implications for management. Eur Respir J 10:1640–1647, 1997

14) Reichardt HM, Kaestner KH, Tuckerman J, Kreiz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angerl P, Schutz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93:531–541, 1998

15) Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 15:943–953, 1995

16) Leung DY, Hamid Q, Vottero A, Szefler SJ, Surs WJ, Minshall E, Chrousos GP, Klemm DJ. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 186:1567–1574, 1997

17) Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61(Suppl III):i40–i50, 2002

18) Shahidi H, Vottero A, Stratakis CA, Taymans SE, Karl M, Longui CA, Chrousos GP, Daughaday WH, Gregory SA, Plate JM. Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. Biochem Biophys Res Commun 254:559–565, 1999

19) Korn SH, Wouters EF, Wesseling G, Arends JW, Thunnissen FB. In vitro and in vivo modulation of alpha- and beta-glucocorticoid-receptor mRNA in human bronchial epithelium. Am J Respir Crit Care Med 155:1117–1122, 1997

20) Oakley RH, Sar M, Cidlowski JA. The human glucocorticoid receptor beta isoform: expression, biochemical properties, and putative function. J Biol Chem 271:9550–9559, 1996

21) Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, Gentit E, Collins T. Nuclear integration of glucocorticoid receptor and nuclear factor-kappa B signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 273:29291–29294, 1998

22) de Lange P, Kuper JW, Huizenga NA, Brinkmann AO, de Jong FH, Karl M, Chrousos GP, Lamberts SW. Differential hormone dependent transcriptional activation and repression by naturally occurring human glucocorticoid receptor variants. Mol Endocrinol 11:1156–1164, 1997

23) Hecht K, Carlstedt-Duke J, Stierna P, Gustafsson J, Bronnegard M, Wikstrom AC. Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor. J Biol Chem 272:26659–26664, 1997

24) Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM. Regulation of the human interleukin-2 gene by the alpha and beta isoforms of the glucocorticoid receptor. Mol Cell Endocrinol 136:23–28, 1997